摘要
目的探讨FOLFOX46与XELOX方案在进展期结直肠癌术后辅助化学治疗的疗效。方法选择2012年1月到2014年5月接诊的200例进展期结直肠癌患者进行研究。按照随机数表法分为观察组和对照组。观察组150例患者,采用FOLFOX46方案辅助化学治疗。对照组50例患者,采用XELOX方案辅助化学治疗。比较两组患者的治疗情况、3年的无病生存(DFS)率及总生存(OS)率、不良反应。结果观察组患者与对照组患者的治疗完成率均为76.00%(P>0.05);观察组患者治疗未完成率(过敏原因、病情变化、经济原因、其他)与对照组患者相比较无统计学差异(P>0.05);Ⅱ期患者中,观察组3年的DFS率为87.23%,对照组为为83.33%,两组比较无统计学意义(P>0.05);观察组3年的OS率(91.49%)高于对照组(88.89%),两组比较无显著差异(P>0.05);Ⅲ期患者中,观察组3年的DFS率为81.11%,对照组为为77.78%,两组比较无统计学意义(P>0.05);观察组3年的OS率(87.78%)高于对照组(86.67%),两组比较无显著差异(P>0.05);观察组患者的不良反应与对照组相比差异无统计学意义(P>0.05)。结论 FOLFOX46与XELOX方案在进展期结直肠癌术后辅助化学治疗的疗效相近。
Objective To evaluate the clinical of FOLFOX46 with XELOX program in advanced colorectal cancer adjuvant chemotherapy. Methods 200 patients with advanced colorectal cancer from September January 2012 to May 2014 were researched. According to a random number table method,they were divided randomly into observation and control groups. observation group had 150 patients,they were treated by using of FOLFOX46 adjuvant chemotherapy. Control group had 50 patients,using XELOX adjuvant chemotherapy. Two groups＇ treatment,3-year DFS rate and OS rates,adverse reactions were compared. Results Treatment completion rate in the observation group and the control group was 76. 00 %（ P〉0. 05）; There was no significant difference of patients in the control group and the observation group in treatment no completion rate（ allergy reasons,changes in condition,economic reasons,other）（ P〉0. 05）; Ⅱ patients,3- year DFS rate in the observation group was 87. 23 %,3- year DFS rate in the control group was 83. 33 %,there were no significant differences compared to each other（ P〉0. 05）; 3- year OS rate in the observation group（ 91. 49 %） was higher than the control group（ 88. 89 %）,there was a significant difference（P〉0. 05）; Ⅲ patients,3- year DFS rate in the observation group was 81. 11 %,3- year DFS rate in the control group was 77. 78 %,there were no significant differences compared to each other（ P〉0. 05）; 3- year OS rate in the observation group（ 87. 78 %） was higher than the control group（ 86. 67 %）,there was a significant difference（ P〉0. 05）; there was no significant difference of patients in the control group and the observation group in adverse reactions（ P〉0. 05）. Conclusion The efficacy of FOLFOX46 with XELOX program in advanced colorectal cancer adjuvant chemotherapy is similar.
出处
《临床和实验医学杂志》
2016年第2期155-157,共3页
Journal of Clinical and Experimental Medicine
